Latest Pharma Insights
Taubert Departs J&J On Growth Trajectory, Ahead Of Darzalex LOE
As top exec of Johnson & Johnson’s pharmaceutical unit, Taubert delivered on ambitious growth goals and helped build a pipeline of promising brands. North America Innovative Medicines chairman Tom Cavanaugh will succeed her.
Scrip - August 4, 2026
As top exec of Johnson & Johnson’s pharmaceutical unit, Taubert delivered on ambitious growth goals and helped build a pipeline of promising brands. North America Innovative Medicines chairman Tom Cavanaugh will succeed her.
Scrip - August 4, 2026
Winrevair’s Steep Growth Paces Merck’s Q2 Financial Performance
With PAH drug Winrevair up 75% year-over-year and COPD drug Ohtuvayre off to a solid launch, the cardiometabolic/respiratory disease franchise drove second-quarter growth for Merck.
Scrip - August 4, 2026
With PAH drug Winrevair up 75% year-over-year and COPD drug Ohtuvayre off to a solid launch, the cardiometabolic/respiratory disease franchise drove second-quarter growth for Merck.
Scrip - August 4, 2026
Pfizer Says Seagen Acquisition Exceeding Expectations Despite Phase III Miss
The four commercial cancer drugs acquired in the 2023 acquisition are on pace to generate about $4bn in sales this year, and Pfizer remains encouraged about the prospects for sigvotatug vedotin.
Scrip - August 4, 2026
The four commercial cancer drugs acquired in the 2023 acquisition are on pace to generate about $4bn in sales this year, and Pfizer remains encouraged about the prospects for sigvotatug vedotin.
Scrip - August 4, 2026
NTAP Alternative Pathway Gone, CJR-X Delayed: What FY2027 IPPS Means For Medtech
CMS finalized a 2.3% FY2027 inpatient payment rate increase and eliminated the alternative NTAP pathway for FDA breakthrough devices, while delaying the CJR-X joint replacement payment model to Jan. 1, 2028.
Medtech Insight - August 4, 2026
CMS finalized a 2.3% FY2027 inpatient payment rate increase and eliminated the alternative NTAP pathway for FDA breakthrough devices, while delaying the CJR-X joint replacement payment model to Jan. 1, 2028.
Medtech Insight - August 4, 2026
Lilly’s Opportunistic, Deal Type-Agnostic Approach To Business Development
Lilly’s business development chief Jake Van Naarden reviews the firm’s 31 deals so far in 2026 and the strategies and priorities underlying that activity.
In Vivo - August 4, 2026
Lilly’s business development chief Jake Van Naarden reviews the firm’s 31 deals so far in 2026 and the strategies and priorities underlying that activity.
In Vivo - August 4, 2026
P&G Bringing Its Global Footprint To Personalized Nutrition Sector
Procter & Gamble has $3.8bn agreement to acquire Thorne, which its health care division chief calls “a highly trusted brand at the forefront of personalized health.”
HBW Insight - August 4, 2026
Procter & Gamble has $3.8bn agreement to acquire Thorne, which its health care division chief calls “a highly trusted brand at the forefront of personalized health.”
HBW Insight - August 4, 2026
Freshness Index 2025: Big Pharma’s Aging Portfolio Problem Is Getting Worse
Big pharma companies must replenish aging portfolios with innovative therapies. This is no easy task and the numbers suggest the industry is falling further behind.
Scrip - August 4, 2026
Big pharma companies must replenish aging portfolios with innovative therapies. This is no easy task and the numbers suggest the industry is falling further behind.
Scrip - August 4, 2026
Could Blister Packs Finally Be Recycled at Scale?
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026
Global Medtech Guidance Tracker: July 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 90 documents have been posted on the tracker since its last update.
Medtech Insight - August 4, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 90 documents have been posted on the tracker since its last update.
Medtech Insight - August 4, 2026
KKR’s $5.7Bn Bet On Integer Reopens The Door For Private Equity In Medtech
KKR's $5.7bn take-private of Integer Holdings reflects a broader private equity push into medtech, with depressed valuations and non-cyclical revenue making device contract manufacturers an increasingly attractive target for financial sponsors.
Medtech Insight - August 4, 2026
KKR's $5.7bn take-private of Integer Holdings reflects a broader private equity push into medtech, with depressed valuations and non-cyclical revenue making device contract manufacturers an increasingly attractive target for financial sponsors.
Medtech Insight - August 4, 2026
Accelerating Influenza Development: Lessons from a Novel Influenza Prevention Candidate
How can the right clinical development strategy help accelerate progress from early proof of concept to later-stage trials?
Scrip - August 4, 2026
How can the right clinical development strategy help accelerate progress from early proof of concept to later-stage trials?
Scrip - August 4, 2026
Bayer Slams Germany’s Pricing Approach As It Lays Out Asundexian Launch Plans
Bayer’s CEO Bill Anderson has raised concerns around pricing policy in Germany as the German major gears up to launch its potential blockbuster asundexian.
Scrip - August 4, 2026
Bayer’s CEO Bill Anderson has raised concerns around pricing policy in Germany as the German major gears up to launch its potential blockbuster asundexian.
Scrip - August 4, 2026
Off-Patent, On Record: View Through The Journalist’s Lens With Generics Bulletin’s Dave Wallace
Generics Bulletin senior reporter Urt? Fultinavi?i?t? is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.
Generics Bulletin - August 4, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.
Generics Bulletin - August 4, 2026
UK Hydrocortisone Appeal Loss Strengthens CMA Hand In Excessive Pricing Cases
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
Generics Bulletin - August 4, 2026
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
Generics Bulletin - August 4, 2026
Will A Patent Cliff Spark The Biggest Merger Of All Time?
Bristol Myers Squibb’s looming patent cliff puts nearly 70% of its first-half revenues at risk, raising doubts over whether its pipeline can offset the decline of Eliquis, Opdivo and other major franchises.
Generics Bulletin - August 4, 2026
Bristol Myers Squibb’s looming patent cliff puts nearly 70% of its first-half revenues at risk, raising doubts over whether its pipeline can offset the decline of Eliquis, Opdivo and other major franchises.
Generics Bulletin - August 4, 2026
Podcast: China’s Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 4, 2026
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 4, 2026
What Next After Indian Regulator’s Hammer Falls On Ethics Committees?
Are clinical trial disruptions or drug shortages expected as the Indian drug regulator recently made unprecedented public disclosures of punitive measures against eight ethics committees after cancelling licenses of some production units earlier this year? Scrip spoke to experts
Scrip - August 4, 2026
Are clinical trial disruptions or drug shortages expected as the Indian drug regulator recently made unprecedented public disclosures of punitive measures against eight ethics committees after cancelling licenses of some production units earlier this year? Scrip spoke to experts
Scrip - August 4, 2026
Biotech Investors Are Waiting For The Wrong Milestone In AI Drug Discovery
Converge Bio's Dov Gertz says the value in AI drug discovery compounds at the platform layer, years before a candidate meets a regulator, and the milestones that reveal it can be measured now.
In Vivo - August 4, 2026
Converge Bio's Dov Gertz says the value in AI drug discovery compounds at the platform layer, years before a candidate meets a regulator, and the milestones that reveal it can be measured now.
In Vivo - August 4, 2026
Over The Counter: Realizing Growth Through Pharmacy, With Simon-Kucher
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026
Hemispheric Bets AI Can Give The Brain Its First Objective Test
Fresh out of stealth with $52m, the NeuroAI startup Hemispheric says its Descartes model can decode EEG into clinical insights.
Medtech Insight - August 4, 2026
Fresh out of stealth with $52m, the NeuroAI startup Hemispheric says its Descartes model can decode EEG into clinical insights.
Medtech Insight - August 4, 2026
L’Oréal Outlines ‘Ambitious’ Gucci Beauty Plans
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026
Nicotine, Tobacco Researchers Suggest Doctors Recommend E-Cigarettes For Smoking Cessation
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026
Taubert Departs J&J On Growth Trajectory, Ahead Of Darzalex LOE
As top exec of Johnson & Johnson’s pharmaceutical unit, Taubert delivered on ambitious growth goals and helped build a pipeline of promising brands. North America Innovative Medicines chairman Tom Cavanaugh will succeed her.
Scrip - August 4, 2026
As top exec of Johnson & Johnson’s pharmaceutical unit, Taubert delivered on ambitious growth goals and helped build a pipeline of promising brands. North America Innovative Medicines chairman Tom Cavanaugh will succeed her.
Scrip - August 4, 2026
Winrevair’s Steep Growth Paces Merck’s Q2 Financial Performance
With PAH drug Winrevair up 75% year-over-year and COPD drug Ohtuvayre off to a solid launch, the cardiometabolic/respiratory disease franchise drove second-quarter growth for Merck.
Scrip - August 4, 2026
With PAH drug Winrevair up 75% year-over-year and COPD drug Ohtuvayre off to a solid launch, the cardiometabolic/respiratory disease franchise drove second-quarter growth for Merck.
Scrip - August 4, 2026
Pfizer Says Seagen Acquisition Exceeding Expectations Despite Phase III Miss
The four commercial cancer drugs acquired in the 2023 acquisition are on pace to generate about $4bn in sales this year, and Pfizer remains encouraged about the prospects for sigvotatug vedotin.
Scrip - August 4, 2026
The four commercial cancer drugs acquired in the 2023 acquisition are on pace to generate about $4bn in sales this year, and Pfizer remains encouraged about the prospects for sigvotatug vedotin.
Scrip - August 4, 2026
Freshness Index 2025: Big Pharma’s Aging Portfolio Problem Is Getting Worse
Big pharma companies must replenish aging portfolios with innovative therapies. This is no easy task and the numbers suggest the industry is falling further behind.
Scrip - August 4, 2026
Big pharma companies must replenish aging portfolios with innovative therapies. This is no easy task and the numbers suggest the industry is falling further behind.
Scrip - August 4, 2026
Accelerating Influenza Development: Lessons from a Novel Influenza Prevention Candidate
How can the right clinical development strategy help accelerate progress from early proof of concept to later-stage trials?
Scrip - August 4, 2026
How can the right clinical development strategy help accelerate progress from early proof of concept to later-stage trials?
Scrip - August 4, 2026
Bayer Slams Germany’s Pricing Approach As It Lays Out Asundexian Launch Plans
Bayer’s CEO Bill Anderson has raised concerns around pricing policy in Germany as the German major gears up to launch its potential blockbuster asundexian.
Scrip - August 4, 2026
Bayer’s CEO Bill Anderson has raised concerns around pricing policy in Germany as the German major gears up to launch its potential blockbuster asundexian.
Scrip - August 4, 2026
Podcast: China’s Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 4, 2026
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 4, 2026
What Next After Indian Regulator’s Hammer Falls On Ethics Committees?
Are clinical trial disruptions or drug shortages expected as the Indian drug regulator recently made unprecedented public disclosures of punitive measures against eight ethics committees after cancelling licenses of some production units earlier this year? Scrip spoke to experts
Scrip - August 4, 2026
Are clinical trial disruptions or drug shortages expected as the Indian drug regulator recently made unprecedented public disclosures of punitive measures against eight ethics committees after cancelling licenses of some production units earlier this year? Scrip spoke to experts
Scrip - August 4, 2026
NTAP Alternative Pathway Gone, CJR-X Delayed: What FY2027 IPPS Means For Medtech
CMS finalized a 2.3% FY2027 inpatient payment rate increase and eliminated the alternative NTAP pathway for FDA breakthrough devices, while delaying the CJR-X joint replacement payment model to Jan. 1, 2028.
Medtech Insight - August 4, 2026
CMS finalized a 2.3% FY2027 inpatient payment rate increase and eliminated the alternative NTAP pathway for FDA breakthrough devices, while delaying the CJR-X joint replacement payment model to Jan. 1, 2028.
Medtech Insight - August 4, 2026
Global Medtech Guidance Tracker: July 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 90 documents have been posted on the tracker since its last update.
Medtech Insight - August 4, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 90 documents have been posted on the tracker since its last update.
Medtech Insight - August 4, 2026
KKR’s $5.7Bn Bet On Integer Reopens The Door For Private Equity In Medtech
KKR's $5.7bn take-private of Integer Holdings reflects a broader private equity push into medtech, with depressed valuations and non-cyclical revenue making device contract manufacturers an increasingly attractive target for financial sponsors.
Medtech Insight - August 4, 2026
KKR's $5.7bn take-private of Integer Holdings reflects a broader private equity push into medtech, with depressed valuations and non-cyclical revenue making device contract manufacturers an increasingly attractive target for financial sponsors.
Medtech Insight - August 4, 2026
Hemispheric Bets AI Can Give The Brain Its First Objective Test
Fresh out of stealth with $52m, the NeuroAI startup Hemispheric says its Descartes model can decode EEG into clinical insights.
Medtech Insight - August 4, 2026
Fresh out of stealth with $52m, the NeuroAI startup Hemispheric says its Descartes model can decode EEG into clinical insights.
Medtech Insight - August 4, 2026
P&G Bringing Its Global Footprint To Personalized Nutrition Sector
Procter & Gamble has $3.8bn agreement to acquire Thorne, which its health care division chief calls “a highly trusted brand at the forefront of personalized health.”
HBW Insight - August 4, 2026
Procter & Gamble has $3.8bn agreement to acquire Thorne, which its health care division chief calls “a highly trusted brand at the forefront of personalized health.”
HBW Insight - August 4, 2026
Could Blister Packs Finally Be Recycled at Scale?
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026
Over The Counter: Realizing Growth Through Pharmacy, With Simon-Kucher
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026
L’Oréal Outlines ‘Ambitious’ Gucci Beauty Plans
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026
Nicotine, Tobacco Researchers Suggest Doctors Recommend E-Cigarettes For Smoking Cessation
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026
Off-Patent, On Record: View Through The Journalist’s Lens With Generics Bulletin’s Dave Wallace
Generics Bulletin senior reporter Urt? Fultinavi?i?t? is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.
Generics Bulletin - August 4, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.
Generics Bulletin - August 4, 2026
UK Hydrocortisone Appeal Loss Strengthens CMA Hand In Excessive Pricing Cases
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
Generics Bulletin - August 4, 2026
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
Generics Bulletin - August 4, 2026
Will A Patent Cliff Spark The Biggest Merger Of All Time?
Bristol Myers Squibb’s looming patent cliff puts nearly 70% of its first-half revenues at risk, raising doubts over whether its pipeline can offset the decline of Eliquis, Opdivo and other major franchises.
Generics Bulletin - August 4, 2026
Bristol Myers Squibb’s looming patent cliff puts nearly 70% of its first-half revenues at risk, raising doubts over whether its pipeline can offset the decline of Eliquis, Opdivo and other major franchises.
Generics Bulletin - August 4, 2026
Lilly’s Opportunistic, Deal Type-Agnostic Approach To Business Development
Lilly’s business development chief Jake Van Naarden reviews the firm’s 31 deals so far in 2026 and the strategies and priorities underlying that activity.
In Vivo - August 4, 2026
Lilly’s business development chief Jake Van Naarden reviews the firm’s 31 deals so far in 2026 and the strategies and priorities underlying that activity.
In Vivo - August 4, 2026
Biotech Investors Are Waiting For The Wrong Milestone In AI Drug Discovery
Converge Bio's Dov Gertz says the value in AI drug discovery compounds at the platform layer, years before a candidate meets a regulator, and the milestones that reveal it can be measured now.
In Vivo - August 4, 2026
Converge Bio's Dov Gertz says the value in AI drug discovery compounds at the platform layer, years before a candidate meets a regulator, and the milestones that reveal it can be measured now.
In Vivo - August 4, 2026